Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium

January 26, 2024

https://www.prnewswire.com/news-releases/aadi-bioscience-announces-poster-presentations-at-the-2024-american-society-of-clinical-oncology-asco-genitourinary-gu-cancers-symposium-302045933.html

Real-world genomic analysis highlights unmet medical need in GU cancer patients with TSC1/2 inactivating alterations

LOS ANGELES, Jan. 26, 2024 /PRNewswire/ — Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place January 25-27, 2024, in San Francisco, CA.

Read more at prnewswire.com

Related news for (AADI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.